Articles related to DEPRESSION

“Don’t try to think yourself out of a dysregulated state; it’s a body thing.”

Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Clinicians treating cancer and kidney disease patients prescribed antidepressants at rates similar to outpatient psychiatrists, highlighting the prevalence of depression management across specialties.

The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.